General
Preferred name
BICALUTAMIDE
Synonyms
ICI-176334 ()
CHEMBL409 ()
(R)-BICALUTAMIDE ()
Bicalutamide (Casodex) ()
Bicalutamide (ICI-176334) ()
NSC-759816 ()
ICI 176,334 ()
ICI176,334-1 ()
Kalumid ()
Casodex ()
Calutide ()
Cosudex ()
Bicalutamide-d4 ()
P&D ID
PD000730
CAS
90357-06-5
1185035-71-5
Tags
probe
natural product
drug
available
Approved by
FDA
First approval
1995
Drug Status
approved
withdrawn
Drug indication
Antineoplastic
Prostate cancer
Max Phase
Phase 4
Probe info
Probe selectivity
protein-selective
Probe type
P&D approved
calculated probe
Probe sources
High-quality chemical probes
Tool Compound Set
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Bicalutamide is non-steroidal anti-androgen that binds to the andogen receptor. The INN record for this drug indicates that it is a mixture of stereo-isomers. We show the non-stereo molecule to represent this mixture. (R)-Bicalutamide has PubChem CID 56069. (GtoPdb)
DESCRIPTION Non-steroidal androgen receptor antagonist (Tocriscreen Plus)
DESCRIPTION Synthetic retinoid and RARbeta agonist; also RARalpha and RARgamma antagonist (Tocris Bioactive Compound Library)
Cell lines
371
Organisms
0
Compound Sets
36
AdooQ Bioactive Compound Library
A10142
Axon Medchem Screening Library
3313
Cayman Chemical Bioactives
14250
22377
ChEMBL Approved Drugs
CHEMBL409
ChEMBL Drugs
CHEMBL409
Concise Guide to Pharmacology 2017/18
2863
Concise Guide to Pharmacology 2019/20
2863
Concise Guide to Pharmacology 2021/22
2863
Concise Guide to Pharmacology 2023/24
2863
Drug Repurposing Hub
DrugBank
DB01128
DrugBank Approved Drugs
DB01128
DrugCentral
367
DrugCentral Approved Drugs
367
DrugMAP
DMZMSPF
DrugMAP Approved Drugs
DMZMSPF
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
2863
High-quality chemical probes
PD000730
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL409
Mcule NIBR MoA Box Subset
MCULE-8218577883
MedChem Express Bioactive Compound Library
HY-14249
NCATS Inxight Approved Drugs
A0Z3NAU9DP
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Bicalutamide(Casodex)
TargetMol Bioactive Compound Library
T0380
The Spectrum Collection
Tocris Bioactive Compound Library
3389
Tocriscreen Plus
3389
Tool Compound Set
Welcome Trust Cancer Drugs
150
1502
Withdrawn 2.0
w206
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
430.06
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
2.88
TPSA
107.26
Fraction CSP3
0.22
Chiral centers
1.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Nuclear Receptors
Target
Androgen receptor (ANDR)
Androgen Receptor
AR
AR antagonist
Androgen Receptor,Autophagy
Pathway
Endocrinology/Hormones
Autophagy
Vitamin D Related/Nuclear Receptor
Primary Target
Androgen Receptors
MOA
Antagonist
Androgen Receptor Antagonists
Androgen Receptor antagonist
Member status
member
Indication
prostate cancer
ATC
L02BB03
Toxicity type
cardiovascular
Therapeutic Class
Anticancer Agents
Source data